Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
170 participants
INTERVENTIONAL
2021-05-01
2026-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The aim of the study is to determine whether monitoring the onset of spontaneous urination after fast track knee arthroplasty is safe based on symptoms alone without ultrasound monitoring.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Onset PrevenTIon of Urinary Retention in Orthopaedic Nursing and Rehabilitation
NCT04700969
Impact of Integrated Care Pathways for Prevention of Post-operative Urinary Retention (POUR)
NCT03863743
Comparative Study Between Retained and Non-retained Urinary Catheter in Total Knee Arthorplasty With Epidural Anesthesia
NCT03341819
Determinants for Return to Work After Primary Knee Arthroplasty
NCT04665180
When to Perform Bladder Catheterization in Fast-track Hip and Knee Arthroplasty
NCT02126813
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The primary outcome variable is the change in IPSS score from the baseline to 3 months after the procedure. The baseline score is evaluated preoperatively.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultrasound monitoring group
In the ultrasound group, urinary retention is monitored, according to current practice, with an ultrasound scanner and the patient is catheterized if necessary, if residual urine exceeds 800 ml, or if the patient is symptomatic.
Catheterization based on ultrasound
Bladder volume ultrasound
Symptoms alone group
Urination is monitored by asking at regular intervals about the onset of spontaneous urination and the patient is catheterized only on a symptomatic basis.
Catheterization based on evaluation of symptoms
Ask for symptoms: Need to urinate, lower abdominal pain
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Catheterization based on ultrasound
Bladder volume ultrasound
Catheterization based on evaluation of symptoms
Ask for symptoms: Need to urinate, lower abdominal pain
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* fracture as indication for surgery
* lack of co-operation
* untreated urinary retention
* nephrostoma
* general anesthesia
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Eastern Finland
OTHER
Central Finland Hospital District
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Juha Paloneva, professor
Role: PRINCIPAL_INVESTIGATOR
Chief medical director
Heikki Seikkula, PhD
Role: STUDY_CHAIR
Investigator
Juho Sippola, MD
Role: STUDY_CHAIR
Investigator
Konsta Pamilo, PhD
Role: STUDY_CHAIR
Investigator
Jonne Åkerla, MD
Role: STUDY_CHAIR
Investigator
Aleksi Reito, PhD
Role: STUDY_CHAIR
Investigator
Pirkko Kinnunen
Role: STUDY_CHAIR
Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Central Finland Hospital Nova
Jyväskylä, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Juha Paloneva, MD, PhD
Role: primary
Juho Sippola, MD
Role: backup
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1U/2020
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.